Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

• Status: Recruiting
• Trial end date: 2022-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jon Simmons
• Collaborator: University of South Alabama

Criteria

Inclusion Criteria:

1. Male or Female age 18 or older

2. On high flow oxygen =/> 6 liters nasal cannula (or)

3. On mechanical ventilation

4. Clinical diagnosis of COVID-19 & positive PCR test (or)

5. Clinical diagnosis of COVID-19 & negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan

Exclusion Criteria:

1. Known allergy to Pulmozyme

2. Less than 18 years of age

3. Grave condition with anticipated death within 48 hours; at the discretion of treating physician.

4. Enrollment in another clinical trial receiving investigatory drugs